CURRENT STATIN POSITIONS IN THE PREVENTION OF CARDIOVASCULAR EVENTS

Abstract

Progression of the atherosclerotic process with the development of clinical manifestations is associated with an increased level of atherogenic fractions of lipids, primarily low-density lipoprotein cholesterol. The most studied group of lipid lowering drugs, which have proven their effectiveness in reducing cardiovascular morbidity and mortality, and the first choice drugs in the treatment of dyslipidemia are statins. The updated international guidelines for the treatment of dyslipidemia revised approaches to cardiovascular risk stratification and lipid lowering therapy tactics in different patient cohorts.